Article
Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines.
Cancer chemotherapy and pharmacology - 1 Oct 2016
Meulendijks Didier, Henricks Linda M, van Kuilenburg André B P, Jacobs Bart A W, Aliev Abidin, Rozeman Lisette, Meijer Judith, Beijnen Jos H, de Graaf Hiltje, Cats Annemieke, Schellens Jan H M
Abstract excerpt
PURPOSE: Dihydropyrimidine dehydrogenase (DPD) is a critical determinant of 5-fluorouracil pharmacology, and reduced activity of DPD as a result of deleterious polymorphisms in the gene encoding DPD (DPYD) can result in severe treatment-related toxicity. Dosing recommendations to individualize treatment have been provided for three DPYD variants (DPYD*2A, c.2846A>T, and c.1679T>G). A fourth variant,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.